PDEX (51) UTMD (63) PROF (47) STIM (31) ⌘ Pro Terminal →

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) — RQD Stock Rating Cockpit

$10.12 +0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.11

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $202.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.11 (-0.14%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KTWO)Realized 20D OHLCV Swing Band: ±1.8%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY KTWO SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (25% of score)

FRED Regime × Technicals: 99% of 52W Range • RSI-14 at 49.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$10.07+0.3% Next Q

Q2 (-2Q)

Grade D$10.10-0.1% Next Q

Q3 (-1Q)

Grade C-$10.09+0.3% Next Q

Current

Grade D+$10.12-0.9% Hist 90D α

Trajectory: D (45) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KTWO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KTWO currently carries a cautious 53/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.09) and Max Pain ($10.63) forces dealer call-delta covering toward $11.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KTWO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KTWO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

49.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE99% OF RANGE

L: $10$10.12H: $10

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on KTWO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

17/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like KTWO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KTWO)

✓Walkthrough of KTWO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KTWO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.91%⚡ TESTING RESISTANCE

2026-10-30O $10.09H $10.12L $10.09C $10.12VOL 15.8K

RES: $10.12SUP: $9.96SMA50: $10.09SMA200: $9.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KTWO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KTWO Butterfly Map → + Track KTWO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KTWO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KTWO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KTWO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KTWO)

Health Care Rank #307 of 1016 ⚔️ PDEX vs KTWO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KTWO vs. PDEX, UTMD, PROF, STIM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) ranks #307 by composite RQD confidence (53/100, grade D+) and #577 by equity capitalization ($202.8M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with KTWO at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KTWO ACTIVE K2 Capital Acquisition Corporation Class A Ordinary Share	D+	53/100	—	—	—	+0.30%	$202.8M	Benchmark Subject
PDEX Pro-Dex Inc.	D	51/100	22.2x	29.3%	23.2%	-2.52%	$199.2M	/pdex-vs-ktwo →
UTMD Utah Medical Products Inc.	C	63/100	—	57.1%	26.9%	-2.96%	$212.7M	/utmd-vs-ktwo →
PROF Profound Medical Corp.	D	47/100	—	70.8%	-35.0%	+1.38%	$214.1M	/prof-vs-ktwo →
STIM Neuronetics Inc.	E	31/100	—	48.5%	-35.0%	+5.31%	$181.3M	/stim-vs-ktwo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002086524

In its most recent audited fiscal period (FY2025, filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KTWO closed FY2025 with $754.7K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$754.7K	—

3. KTWO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KTWO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $10.12 (+0.30% 1D, market cap $202.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KTWO ranks #307 in composite RQD confidence.

How does KTWO compare to PDEX and UTMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PDEX (Pro-Dex Inc.) holds a D grade (51/100 RQD, P/E 22.2x, ROIC 23.2%, cap $199.2M) and UTMD (Utah Medical Products Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 26.9%, cap $212.7M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KTWO?

Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $0 in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KTWO trading relative to its 50-day, 200-day, and 52-week technical levels?

KTWO last traded at $10.12 (+0.30% on volume of 164 shares), positioning the stock +0.30% above its 50-day simple moving average ($10.09) and +1.40% above its 200-day simple moving average ($9.98). Across its 52-week range of $9.84 to $10.12, KTWO sits at the 100.0% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±1.8% ($9.94 to $10.30).

KTWO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KTWO stock right now?

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) currently earns a Roarable Rating of D+ (Sell — SELL) with 53/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is KTWO's 12-month price target and RQD AI Jury consensus?

KTWO's 12-month base price target is $9.89 (range $7.71 to $11.67), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KTWO RQD Cockpit KTWO 12M Forecast KTWO Earnings & Move KTWO Dividends & DRIP KTWO Insiders & 13F KTWO Whale Options KTWO Profit Sankey KTWO News & Why